Page 12 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $3.08
52wk Low $0.20 Atara Biotherapeutics, Inc. ATRA $0.71
2380 Conejo Spectrum Street
Thousand Oaks, CA 91320

(USD - in millions) www.atarabio.com
Market Cap 84.5
Enterprise 93.3
Basic Shares Out. 119.36 COMPANY OVERVIEW
Float 90.37
Institutional Holdings 41.72% Detailed Analysis:Channelchek.com
Short Interest 11.23
Avg. 90-Day Volume 2.85 Atara is harnessing the natural power of the immune system to develop
off-the-shelf cell therapies for difficult-to-treat cancers and autoimmune
conditions that can be rapidly delivered to patients from inventory. With
cutting-edge science and differentiated approach, Atara is the first
EPS Data company in the world to receive regulatory approval of an allogeneic T-
cell immunotherapy. Our advanced and versatile T-cell platform does
2021 2022 2023 not require T-cell receptor or HLA gene editing and forms the basis of a
CQ1 (0.86) (0.87) (0.72) diverse portfolio of investigational therapies that target EBV, the root
CQ2 (0.91) (0.31) (0.68) cause of certain diseases, in addition to next-generation AlloCAR-Ts
designed for best-in-class opportunities across a broad range of
CQ3 (0.90) (0.82) (0.66) hematological malignancies and B-cell driven autoimmune diseases.
CQ4 (0.96) (0.72) (0.56)
CY (3.63) (2.73) (2.61) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) -0.93
ROE (ttm) -2014.86
Debt-to-Total Cap. (mrq) NM
Fiscal Year End 31-Dec

2380 Conejo SThousand OakCA 91320

Key Executives
CEO: Touchon, Pascal
CFO: Hyllengren, Eric
COO: N/A
IR: Chapman, Alex
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures